Related Experiment Video

Updated: May 28, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers

Xanthia F Samaropoulos1, Laney Light, Walter T Ambrosius

  • 1Wake Forest School of Medicine, Division of Public Health Sciences, Medical Center Boulevard, Winston-Salem, NC 27157, United States. xsamarop@wakehealth.edu

Diabetes Research and Clinical Practice
|October 25, 2011
PubMed
Abstract

Insights

Intensive glycemic control lowered inflammation markers like hs-CRP in type 2 diabetes patients. However, increased adiposity diminished these benefits, highlighting the complex interplay between diabetes management and cardiovascular health.

Area of Science:

  • Cardiovascular Disease Research
  • Diabetes Mellitus Management
  • Inflammation Biomarkers

Background:

  • Middle-aged and older adults with type 2 diabetes and cardiovascular disease (CVD) risk factors often exhibit elevated inflammation.
  • Managing cardiovascular risk factors is crucial for improving outcomes in this population.

Purpose of the Study:

  • To investigate if intensive risk factor management reduces inflammation markers in type 2 diabetes patients with CVD or at risk.
  • To determine if adiposity mediates the effects of intensive management on inflammation.

Main Methods:

  • Utilized data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, a large randomized controlled trial.
  • Assessed biomarkers, including high-sensitivity C-reactive protein (hs-CRP), in a subset of 562 participants.
  • Employed linear regression models to analyze intervention effects on inflammation markers.

Main Results:

  • Intensive glycemic control significantly reduced hs-CRP levels compared to standard control (p=0.029).
  • Adjusting for changes in body mass index (BMI) or waist circumference amplified the reduction in hs-CRP between glycemic intervention groups (p<0.001 and p<0.002).

Conclusions:

  • Intensive glycemic control effectively lowered hs-CRP in individuals with type 2 diabetes.
  • Increased adiposity during the intervention attenuated the positive impact of intensive glycemic control on reducing hs-CRP.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...